Ch Biotech R And D Co
Ch Biotech R&D Co., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia. Founded in 2002, the company has established itself as a pioneer in biopharmaceutical research and development, focusing on innovative solutions for healthcare challenges. Specialising in the development of biologics and biosimilars, Ch Biotech R&D Co. is recognised for its commitment to quality and scientific excellence. Their core products include advanced therapeutic proteins and monoclonal antibodies, which are distinguished by their efficacy and safety profiles. With a strong market position, Ch Biotech R&D Co. has achieved significant milestones, including successful collaborations with global pharmaceutical firms. Their dedication to research and development continues to drive advancements in the biotechnology industry, making them a trusted name in biopharmaceutical innovation.
DitchCarbon Score
How does Ch Biotech R And D Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ch Biotech R And D Co's score of 28 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ch Biotech R And D Co's reported carbon emissions
In 2022, CH Biotech R&D Co., headquartered in Taiwan (TW), reported total carbon emissions of approximately 4,000,000 kg CO2e. This figure includes 437,910 kg CO2e from Scope 1 emissions, 3,260,880 kg CO2e from Scope 2 emissions, and 140,920 kg CO2e from Scope 3 emissions. The company has shown a commitment to transparency by disclosing emissions across all three scopes. Comparatively, in 2021, the global emissions were slightly higher, with Scope 1 emissions at 444,390 kg CO2e, Scope 2 at 3,458,040 kg CO2e, and Scope 3 at 92,920 kg CO2e. Notably, in 2021, the company reported only mobile combustion emissions of 7,700 kg CO2e in Taiwan, indicating a focus on specific emission sources. Despite the detailed emissions reporting, CH Biotech R&D Co. has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company’s climate strategy appears to be in the early stages, with no significant pledges or initiatives currently in place. Overall, while CH Biotech R&D Co. has made strides in emissions reporting, further commitments and reduction strategies will be essential for aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 444,390 | 000,000 |
| Scope 2 | 3,458,040 | 0,000,000 |
| Scope 3 | 92,920 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ch Biotech R And D Co is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
